Upload
marlene-reed
View
216
Download
0
Tags:
Embed Size (px)
Citation preview
Impact of Multi-Tiered Copayments on Cost and Use of Prescription Drugsamong the Elderly
Presented at AcademyHealth Annual Research Meeting
Presented by Boyd Gilman, PhDJohn Kautter, PhD
June 28, 2005
411 Waverley Oaks Road, Suite 330 · Waltham, MA 02452-8414Phone: 781-788-8100 x187 · Fax: 781-788-8101, [email protected]
2
Purpose of Study
To evaluate the impact of multi-tiered copayments on cost and use of prescription drugs among the elderly in employer-sponsored health plans
To assess the differential effects for enrollees who are taking drugs primarily for treatment of chronic conditions
To decompose overall impact into a ‘price’ effect (due to higher copay for all drugs) and a ‘substitution’ effect (due to wider differential between copay for similar drugs)
3
Policy Motivation
Medicare will start offering a prescription drug benefit (Part D) on January 1, 2006
Part D will be administered through private health plans that are allowed to set their own enrollee cost sharing rules as long as they: Are actuarially equivalent to standard benefit Do not discriminate against beneficiaries by
increasing cost sharing of a drug used for a particular illness
Employers may drop retiree coverage, forcing retirees to purchase Part D
4
Copayment Structures
Apply fixed enrollee payment amounts to different types of drugs depending on payee preferences Tier 1 for generic drugs Tier 2 for preferred brand name drugs Tier 3 for non-preferred brand name drugs
Tiered copayments are designed to: encourage generic substitution reduce use of drugs with low therapeutic value limit plan spending
5
Use of Tiered Rx Copayments among Retiree Health Plans
According to KFF survey of employer-sponsored retiree health plans: 81% of firms use multi-tiered Rx copays Use of 3-tiered programs grew from 55% in
2003 to 58% in 2004 (2-tiered plans fell) Average Rx copays in 3-tiered plans are:
$10 for generic $20 for preferred brand name $35 for non-preferred brand name
6
Current Literature
Studies suggest that tiered copays may lower use of drugs Motheral & Fairman (2001) Joyce, Goldman & Escarce (2002, 2004) Huskamp (2003) Briesacher & Kamal-Bahl (2004)
Study suggests that lower use may be caused by substitution of mail order prescriptions with longer days supply Thomas & Wallack (2003)
7
Data
Medstat’s 2002 MarketScan databases: Medicare Supplemental and COB File
Enrollment info for over 1 million enrollees in retiree health plans
Rx claims for enrollees Medical claims for enrollees
Benefit Plan Design File Extracts information on Rx and
medical benefit features
8
Important Sample Caveats
Benefit plan information extracted for only 27 health plans
27 health plans drawn from only 10 firms, with almost very little intra-firm variation in drug benefits
Less than ½ enrollees are linkable to benefit plan design file
Several important plan design features are reported as unknown
High degree of correlation between plan design features
Sample based on large, unionized, self-insured firms, and thus not representative of Medicare population
9
Classification of Plans by Drug Copayments
Plan Category
No. of Plans
No. of Tiers Generic
BN - Pref.
BN - N/Pref. Generic BN
A 2 1 5 5 5 - -B 4 1 10 10 10 - -C 2 2 5 10 10 - -D 1 2 5 20 20 - -E 1 3 5 15 25 - -F 4 3 5 15 35 - -G 1 3 6 15 25 - -H 4 3 10 15 30 - -I 2 3 10 25 35 - -J 4 Coins. - - - 20 20K 2 Coins. - - - 30 30
Copay Amount ($) Coins. Rate (%)
10
Enrollment and Drug Payments by Copayment Tier
No. of % ofTier Enrollees Claimants Total Enrollee % OOP
1 318,512 90.5 $2,531 $276 10.92 496 80.2 $2,473 $298 12.13 69,188 88.9 $2,028 $528 26.0
Mean Drug Payments
11
Basic Model
Accessi = + 1 Demographicsi
+ 2 Health Statusi
+ 3 Plan Characteristicsi
+ 4 Medical Benefitsi
+ 5 Drug Benefitsi
+ εi
12
Model Outcomes
Access outcomes Number of prescriptions filled –
normalized by 30-days supply to account for potential mail-order substitution
Total drug expenditures – measured as ingredient costs to account for differences in dispensing fees
Other outcomes Enrollee drug payments Percent of prescriptions filled by generic
drugs
13
Model Covariates
Demographic Characteristics AgeGenderActively working
Health Status Long-term disabilityHCC Risk score
Plan Characteristics Managed care
Medical Benefits Physician copay
Drug Benefits Tier level(Copay amount)
14
Estimation Procedure
Outcomes annualized to adjust for proportion of year enrolled
Generalized linear model weighted by proportion of year enrolled
Standard errors adjusted for within-firm correlation of error terms
Payments estimated over claimants only (roughly 90% of enrollees submitted claim)
Models run separately over claims for drugs used primarily to treat chronic conditions
15
Impact of 3-Tiered Copayment Program on Use and Cost of Rx
Number of Rx Filled -7.2 *** -2.9 ***
Total Payments ($) -336 *** -121 ***
Enrollee Payments ($) 185 *** 136 ***
Percent Filled with Generics (%) 4.3 *** 6.0 ***
Results from regression analysis.
Omitted category = 1 & 2 tiered plans.
ConditionEnrollees
Enrollees withChronicAll
16
What’s driving these results: copay amounts or copay tiers?
Copayment programs are designed to promote: Efficient use of drugs by raising the price of
all drug equivalents (i.e., increasing copay amounts)
Generic substitution by widening the price differential between drug equivalents (i.e., increasing copay differentials)
17
Price and Substitution Effects
‘Price effect’ measures the change in drug use following a change in marginal copays of drug equivalents. Likely to lead to higher total spending and lower
drug use.
‘Substitution effect’ measures the change in drug use following a change in the copay differentials between drug equivalents. Likely to lead to lower total spending with little
change on total use.
18
Decomposition Model
Accessi = + 1-4 Other Covariatesi
+ 5 Copay Leveli
+ 6 Copay Differentiali
+ εi
Copay level = lowest plan copay amount
Copay differential = difference between highest and lowest plan copay
19
Decomposing the Price & Substitution Effects
Number of Rx Filled -8.8 ** -6.1 ***
Total Payments ($) -1.2 -5.4 ***
Enrollee Payments ($) 154.2 *** 18.5 ***
Percent Filled with Generics (%) -10.9 *** 3.3 ***
Price EffectSubstitution
EffectPercent change associated with:
$5 increase in lowest copay
amount
$5 increase in diff. betw. lowest
and highest copays
20
Conclusions
More aggressive enrollee cost sharing is associated with:
Fewer prescriptions filled
Lower total payments and higher enrollee payments
Higher proportion of Rx filled by generics
Smaller reduction in drug use and greater generic substitution among those with chronic conditions
Increasing copay differentials through multi-tiered program associated with:
Greater generic substitution
Smaller reduction in use of drugs
21
Policy Implications
More aggressive enrollee cost sharing may promote efficient use of Rx, but may also create barriers to access
Multi-tiered programs may be better than higher marginal copays for achieving efficiency without sacrificing access
Responsiveness to price incentives and, thus, impact on access, may vary depending on type of condition treated
Need to monitor impact of enrollee cost sharing programs on access and health outcomes in Part D plans